NeoGenomics (NEO) Projected to Post Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) is anticipated to post its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect NeoGenomics to post earnings of $0.02 per share and revenue of $183.8520 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, October 28, 2025 at 8:30 AM ET.

NeoGenomics Stock Performance

NEO stock opened at $10.59 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.58 and a current ratio of 3.92. The stock has a market cap of $1.37 billion, a P/E ratio of -13.07 and a beta of 1.61. The firm has a 50 day simple moving average of $8.05 and a 200 day simple moving average of $7.71. NeoGenomics has a 52 week low of $4.72 and a 52 week high of $19.11.

Institutional Trading of NeoGenomics

A number of institutional investors have recently added to or reduced their stakes in the business. State of Tennessee Department of Treasury lifted its stake in NeoGenomics by 3.6% in the second quarter. State of Tennessee Department of Treasury now owns 58,082 shares of the medical research company’s stock valued at $425,000 after acquiring an additional 2,039 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of NeoGenomics by 3.6% in the second quarter. The Manufacturers Life Insurance Company now owns 65,004 shares of the medical research company’s stock valued at $475,000 after purchasing an additional 2,238 shares during the period. Creative Planning raised its position in shares of NeoGenomics by 20.4% in the second quarter. Creative Planning now owns 16,735 shares of the medical research company’s stock valued at $122,000 after purchasing an additional 2,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of NeoGenomics by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 75,798 shares of the medical research company’s stock valued at $719,000 after purchasing an additional 3,254 shares during the period. Finally, Headlands Technologies LLC bought a new position in shares of NeoGenomics in the second quarter valued at approximately $32,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on the stock. TD Cowen raised their price target on shares of NeoGenomics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Morgan Stanley set a $8.00 price target on shares of NeoGenomics and gave the stock an “equal weight” rating in a report on Wednesday, July 30th. BTIG Research restated a “neutral” rating on shares of NeoGenomics in a report on Wednesday, July 30th. Cowen restated a “buy” rating on shares of NeoGenomics in a report on Friday, September 12th. Finally, Piper Sandler set a $11.00 price target on shares of NeoGenomics and gave the stock an “overweight” rating in a report on Monday, August 4th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $12.56.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.